BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint

DOI10.1002/SIM.9265zbMATH Open1547.62247MaRDI QIDQ6626777

Y. Zang, Beibei Guo

Publication date: 29 October 2024

Published in: Statistics in Medicine (Search for Journal in Brave)

zbMATH Keywords

subgroupsimmune responseimmunotherapybiomarkerdose findingphase I/II trialBayesian adaptive designprogression-free survivalrisk-benefit tradeoff

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites Work

• Title not available (Why is that?)
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• A weakly informative default prior distribution for logistic and other regression models
• Bayesian model averaging: A tutorial. (with comments and a rejoinder).
• Robust EM Continual Reassessment Method in Oncology Dose Finding
• A Bayesian Phase I/II Trial Design for Immunotherapy
• Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
• BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons
• A Bayesian design for phase I cancer therapeutic vaccine trials
• uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials
• Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups
• A Bayesian dose finding design for oncology clinical trials of combinational biological agents
• A utility-based Bayesian phase I--II design for immunotherapy trials with progression-free survival end point
• Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times
• A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent

Related Items (1)

Biomarker-based precision dose finding for immunotherapy combined with radiotherapy

This page was built for publication: BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6626777)